Takeda must have liked what it got from the chemoproteomics work out of BridGene Biosciences. The Tokyo-based drugmaker ...
For the fourth year running, Endpoints News will highlight the biotech leaders who are paving the way for the LGBTQ+ ...
Alnylam may be gearing up for its biggest commercial launch yet in its nearly 23-year history, but the company’s top ...
RA Capital leads as most active venture player in private biotech rounds through 2024, with ARCH participating in fewer but ...
Eli Lilly will start selling additional single-dose vials of its weight loss drug Zepbound at a lower price for certain ...
An unusual legal battle over a biotech startup's IPO plans escalated to another level on Valentine's Day, according to two ...
Me CEO Anne Wojcicki and New Mountain Capital propose $2.53/share buyout to take company private, valuing it at $74.7M after ...
Phase 1b US study planned for 2026, as company competes with NS Pharma and Avidity Biosciences in exon 44 space ...
FDA denies Invivyd's EUA expansion for Pemgarda in Covid treatment while BioCryst reports positive Orladeyo data. AN2 changes endpoint, OS Therapies seeks partners & Eyenovia restructures.
Amgen to invest $200M in new Hyderabad tech center through 2025, focusing on AI for drug development. Site opened Monday with ...
Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...
With help from its $43 billion Seagen merger, Pfizer will contribute its antibody-drug conjugates to Summit Therapeutics' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results